Skip to main content

Table 8 Allergic reaction assessment tool based on the CoFAR grading system

From: Protocol for a double-blind, randomized controlled trial on the dose-related efficacy of omalizumab in multi-food oral immunotherapy

 

Grade 1—mild

Grade 2—moderate

Grade 3—severe

Grade 4—life-threatening

Grade 5—death

Intensity

Transient or mild discomfort (˂48 h)

Mild to moderate limitation in activity

Marked limitation in activity

Extreme limitation in activity

 

Assistance

No

May be needed

Usually required

Parenteral medication(s) are usually indicated

Significant assistance required

 

Medical Intervention/Therapy Required

No or minimal

No or minimal

Required

Required

 

Hospitalization

No

Possible

Possible

Probable

 

May include these symptoms

Pruritus

Swelling

Rash

Abdominal discomfort

Other transient symptoms

Persistent hives

Wheezing without dyspnea

Abdominal discomfort/increased vomiting

Other symptoms

Bronchospasm with dyspnea

Severe abdominal pain

Throat tightness with hoarseness

Transient hypotension

Other symptoms

Persistent hypotension and/or hypoxia

Decreased level of consciousness

Associated with collapse and/or incontinence

Other life-threatening symptoms